24 - Emerging Issues in The Global Mpox Threat

Thursday, October 17, 2024

10:30 AM – 11:45 AM US PT

Location: Ballroom (West Hall B)

All relevant financial relationships have been mitigated.

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 1 of PACE contact hours
CE Broker: Maximum of 1 CE broker credit hours

Moderator(s)

Jason Zucker, MD, MS

Assistant Professor of Medicine
Internal Medicine and Pediatrics
Columbia University Irving Medical Center
New York, NY, United States
Aadia Rana, MD (she/her/hers)

Professor of Medicine
University of Alabama-Birmingham Heersink School of Medicine
Birmingham, AL, United States

Faculty(s)

Placide Mbala, PhD (he/him/his)

Head of Epidemiology and Global Department
Institut National de Recherche Biomédicale, DRC
Kinshasa, Kinshasa, Congo, (Congo Â– Kinshasa)
Olivier Tshiani, MD (he/him/his)

Medical Affairs Scientist
Leidos Biomedical research
Rockville, MD, United States
Timothy Wilkin, MD MPH

Chief, Division of Infectious Diseases and Global Public Health
University of California San Diego
San Diego, CA, United States
Agam Rao, MD (she/her/hers)

Medical Officer
Centers for Disease Control and Prevention
Atlanta, GA, United States

Disclosure(s):

Jason Zucker, MD, MS: No financial relationships to disclose

Placide Kingebeni Mbala, PhD: No financial relationships to disclose

Olivier Tshiani, MD: No financial relationships to disclose

Timothy Wilkin, MD MPH: GSK/ViiV Healthcare: Advisor/Consultant (Terminated); Merck and Company, Inc.: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing)

Agam Rao, MD: No financial relationships to disclose

Learning Objectives:

At the conclusion of this session, participants will be able to:

identify the global epidemiology of mpox;
describe clinical benefit of tecovirimat and other antivirals in mpox treatment;
describe recommendations for use of vaccines to prevent mpox.

Presentations:

10:30 AM – 10:50 AM US PT

Global Epidemiology of Mpox in 2024
Speaker: Placide Kingebeni Mbala, PhD (he/him/his) – Institut National de Recherche Biomédicale, DRC
10:50 AM – 11:10 AM US PT

Tecovirimat for the Treatment of Mpox: A Randomized Placebo-controlled Trial in the Democratic Republic of Congo (PALM007)
Speaker: Olivier Tshiani, MD (he/him/his) – Leidos Biomedical research
Co-Author: Lori E. Dodd, PhD – The National Institute of Allergy and Infectious Diseases, National Institutes of Health
Co-Author: Veronique Nussenblatt
11:10 AM – 11:30 AM US PT

Alternative Antiviral Therapies for Treating Severe Mpox Infection
Speaker: Timothy Wilkin, MD MPH – University of California San Diego
11:30 AM – 11:45 AM US PT

Challenging Issues in Mpox Vaccination
Speaker: Agam Rao, MD (she/her/hers) – Centers for Disease Control and Prevention